Associated Press - IRX4204 as a Potential Disease-Modifying Treatment for Alzheimer's Disease
Io Therapeutics, Inc. announced today the presentation of data from preclinical studies of its Retinoid X Receptor (RXR) agonist compound IRX4204 in animal models of Alzheimer's disease, at the 6th Neurodegenerative Conditions Research and Development conference. The studies were directed by Dr. Giulio Pasinetti, The Saunders Family Chair and Professor in Neurology, and Director, Center of Excellence for Novel Approaches to Neurotherapeutics, in the Department of Neurology of Mount Sinai School of Medicine. Dr. Pasinetti said, "The data presented today include studies demonstrating attenuation of cognitive deterioration in IRX4204-treated mouse model of Alzheimer's disease through promotion of electophysiological features in the brain associated with retention of memory function."
- Dr. Giulio Maria Pasinetti, Professor, Neurology, Psychiatry, Geriatrics and Adult Development, Neuroscience, Mount Sinai School of Medicine